Shares of pharmaceutical giant Cipla dropped almost two per cent in early trading despite positive brokerage reports ...

Cipla also allayed concerns that the US government's drug pricing executive order on pharma companies, aimed at lowering cost ...

Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

According to a Moneycontrol analysis as of May 7, 2025, these declines occurred during today's trading session, influenced by ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

In addition, Jefferies expects Tata Motors to see a tough year ahead with the demand for Indian trucks growing soft and the ...

Results: Cipla reported a 30.12% year-on-year increase in Q4FY25 net profit, reaching ₹1,221.84 crore, up from ₹939.04 crore.

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...